or Try an Advanced Search...

    Technical Analysis for KYMR - Kymera Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 30.95 3.69% 1.10
    KYMR closed up 3.69 percent on Monday, July 1, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Flat
    Historical KYMR trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup 0.00%
    Stochastic Buy Signal Bullish 0.00%
    Multiple of Ten Bullish Other 0.00%
    Oversold Stochastic Weakness 0.00%
    Multiple of Ten Bearish Other 3.69%
    Oversold Stochastic Weakness 3.69%
    Multiple of Ten Bullish Other 2.42%
    Oversold Stochastic Weakness 2.42%
    Stochastic Reached Oversold Weakness 3.55%
    Multiple of Ten Bearish Other 3.55%
    Older End-of-Day Signals for KYMR ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 4 hours ago
    Up 1 ATR about 4 hours ago
    10 DMA Resistance about 5 hours ago
    Rose Above 10 DMA about 5 hours ago
    60 Minute Opening Range Breakout about 5 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    KYMR Chart by TradingView
    Basic chart:

    Profile

    Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Disease Autoimmunity Rheumatoid Arthritis Hematologic Malignancies Atopic Dermatitis Dermatitis Hidradenitis Suppurativa

    Is KYMR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 14 Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
    Jun 1 Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
    May 29 Kymera Therapeutics to Participate in Upcoming June Investor Conferences
    May 24 Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
    May 23 Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
    May 22 Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
    May 14 Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
    May 8 Kymera Therapeutics to Participate in Upcoming May Investor Conferences
    May 5 Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think
    May 3 Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
    See more KYMR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 45.31
    52 Week Low 9.6
    Average Volume 550,879
    200-Day Moving Average 28.62
    50-Day Moving Average 34.12
    20-Day Moving Average 32.23
    10-Day Moving Average 30.98
    Average True Range 1.59
    RSI (14) 41.52
    ADX 20.63
    +DI 17.19
    -DI 23.94
    Chandelier Exit (Long, 3 ATRs) 31.85
    Chandelier Exit (Short, 3 ATRs) 34.01
    Upper Bollinger Bands 35.34
    Lower Bollinger Band 29.12
    Percent B (%b) 0.29
    BandWidth 19.28
    MACD Line -1.13
    MACD Signal Line -0.99
    MACD Histogram -0.1364
    Fundamentals Value
    Market Cap 1.84 Billion
    Num Shares 59.4 Million
    EPS -2.86
    Price-to-Earnings (P/E) Ratio -10.82
    Price-to-Sales 46.41
    Price-to-Book 5.59
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 34.18
    Resistance 3 (R3) 33.99 32.74 33.64
    Resistance 2 (R2) 32.74 31.92 32.83 33.46
    Resistance 1 (R1) 31.84 31.41 32.29 32.03 33.28
    Pivot Point 30.59 30.59 30.81 30.68 30.59
    Support 1 (S1) 29.69 29.77 30.14 29.88 28.62
    Support 2 (S2) 28.44 29.26 28.53 28.44
    Support 3 (S3) 27.54 28.44 28.26
    Support 4 (S4) 27.73